Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data

Vassilis G. Giannakoulis, MD1; Eleni Papoutsi, MD1; and Ilias I. Siempos, MD, DSc1,2

abstract

PURPOSE Whether cancer is associated with worse prognosis among patients with COVID-19 is unknown. We aimed to quantify the effect (if any) of the presence as opposed to absence of cancer on important clinical outcomes of patients with COVID-19 by carrying out a systematic review and meta-analysis.

METHODS We systematically searched PubMed, medRxiv, COVID-19 Open Research Dataset (CORD-19), and references of relevant articles up to April 27, 2020, to identify observational studies comparing patients with versus without cancer infected with COVID-19 and to report on mortality and/or need for admission to the intensive care unit (ICU). We calculated pooled risk ratios (RR) and 95% CIs with a random-effects model. The meta-analysis was registered with PROSPERO (CRD42020181531).

RESULTS A total of 32 studies involving 46,499 patients (1,776 patients with cancer) with COVID-19 from Asia, Europe, and the United States were included. All-cause mortality was higher in patients with versus those without cancer (2,034 deaths; RR, 1.66; 95% CI, 1.33 to 2.07; \( P = .0001 \); 8 studies with 37,807 patients). The need for ICU admission was also more likely in patients with versus without cancer (3,220 events; RR, 1.56; 95% CI, 1.31 to 1.87; \( P = .0001 \); 26 studies with 15,375 patients). However, in a prespecified subgroup analysis of patients 65 years of age, all-cause mortality was comparable between those with versus without cancer (915 deaths; RR, 1.06; 95% CI, 0.79 to 1.41; \( P = .71 \); 8 studies with 5,438 patients).

CONCLUSION The synthesized evidence suggests that cancer is associated with worse clinical outcomes among patients with COVID-19. However, elderly patients with cancer may not be at increased risk of death when infected with COVID-19. These findings may inform discussions of clinicians with patients about prognosis and may guide health policies.

JCO Global Oncol 6:799-808. © 2020 by American Society of Clinical Oncology

INTRODUCTION

An ever-increasing number of people in the global population are suffering from cancer.1 Patients with cancer are therefore anticipated to be affected during the current epidemic of COVID-19. However, whether, when infected with COVID-19, patients with versus without cancer are at increased risk for unfavorable clinical outcomes is unknown. This was highlighted in a plenary session at the American Association for Cancer Research Virtual Annual Meeting held on April 27-28, which subsequently issued a call for relevant research.2

We therefore aimed to quantify the effect (if any) of the presence as opposed to absence of cancer on important clinical outcomes, such as mortality and need for admission in the intensive care unit (ICU), of patients with COVID-19 by carrying out a systematic review and meta-analysis.

METHODS

We reported the current systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.3 We prespecified inclusion criteria, methods of data synthesis, and outcomes in a protocol registered in PROSPERO (CRD42020181531) and available online.

Eligibility Criteria

We considered observational cohort studies of COVID-19, which reported on all-cause mortality and/or need for ICU admission of patients with cancer versus patients without cancer. Details on the assessment of need for ICU admission are provided in the Data Supplement. Both peer-reviewed papers and preprints were considered, because of the need for use of rapidly accumulated information during the current situation. Reports on coronavirus-caused diseases other than COVID-19 were excluded.
Search Strategy

We systematically searched PubMed, medRxiv, and CORD-19 (COVID-19 Open Research Dataset). The latter is probably the most extensive machine-readable literature collection specially created for the COVID-19 global crisis. We retrieved all relevant English literature from January 1, 2020, up to April 27, 2020. We also searched references of initially retrieved articles. We used Boolean logic to create
## TABLE 1. Characteristics of Included Studies and Patient Population

| Author          | Country      | Type of Study              | No. of Patients | No. of Patients With Cancer | Female Sex | Median Age (years) | Comorbidities | ARDS | Outcome  |
|-----------------|--------------|----------------------------|----------------|-----------------------------|------------|-------------------|---------------|------|----------|
| Argenziano MG et al¹¹ | Italy        | Multicenter, retrospective cohort | 1,000          | 66 (6.6)                    | 404 (40.4) | 63                | NA            | 297 (35) | ICU       |
| Benelli G et al¹² | Italy        | Single-center, prospective cohort | 411            | 33 (8)                      | 180 (33.4) | 70.5              | 256 (62.3)    | NA    | Death, ICU |
| Chen T et al⁹ | China        | Single-center, retrospective cohort | 55            | 5 (9)                       | 21 (38.2)  | 74                | 37 (67.3)    | > 6 (10.9) | Death    |
| Chen X et al¹⁶ | China        | Multicenter cohort            | 291            | 2 (0.7)                     | 146 (50.2) | 46                | 93 (32)      | NA    | Death    |
| Colaneri M et al¹⁶ | Italy        | Single-center cohort          | 44             | 6 (13.6)                    | 16 (36.3)  | 67.5              | 28 (63.6)    | NA    | ICU       |
| Feng Y et al¹⁷  | China        | Multicenter, retrospective cohort | 476            | 12 (2.5)                    | 205 (43.1) | 53                | 205 (43.1)   | NA    | ICU       |
| Goyal P et al¹⁸a | US           | Multicenter, retrospective cohort | 393            | 23 (5.9)                    | 155 (39.4) | 62.2              | NA            | NA    | Death, ICU |
| Guan W et al¹⁹  | China        | Multicenter, retrospective cohort | 1,590        | 18 (1.1)                    | 686 (42.7) | NA                | 399 (25)     | NA    | Death, ICU |
| Huang C et al²⁰ | China        | Single-center, prospective cohort | 41             | 1 (2)                       | 11 (27)    | 49                | 13 (32)      | 12 (29) | ICU       |
| Jiang X et al²¹ | China        | Single-center, retrospective cohort | 55            | 2 (3.6)                     | 28 (50.9)  | 45                | 29 (52.7)    | 4 (7.3) | ICU       |
| Joharatnam-Hogan N et al²² | UK            | Multicenter, retrospective cohort | 52            | 26 (50)                     | 21 (40.3)  | NA                | NA           | NA    | Death    |
| Li X et al²³    | China        | Single-center, ambispective cohort | 513           | 24 (4.7)                    | 269 (49.1) | 60                | NA           | 210 (38.3) | ICU       |
| Miyashita H et al²⁴ | US           | Multicenter, retrospective cohort | 5,688          | 334 (6)                     | NA         | NA                | NA           | NA    | Death, ICU |
| Myers LC et al²⁵ | US           | Multicenter, retrospective cohort | 377           | 18 (4.8)                    | 165 (43.8) | 61                | NA           | NA    | ICU       |
| Nikpouraghdam M et al²⁶ | Iran        | Single-center, retrospective cohort | 2,964         | 17 (0.57)                   | 1,009 (34) | 56                | 323 (10.89)  | NA    | Death    |
| Petrilli CM et al²⁷ | US           | Multicenter cohort            | 1,582          | 110 (6.9)                   | 580 (36.6) | NA                | 697 (44.0)   | NA    | ICU       |
| Rentsch CT et al²⁸ | US           | Multicenter, retrospective cohort | 585           | 83 (14.2)                   | 27 (4.6)   | 66.1              | NA           | NA    | ICU       |
| Rentsch CT et al²⁸b | US           | Multicenter, retrospective cohort | 4,834         | 587 (12.1)                  | NA         | NA                | NA           | NA    | Death    |
| Rossi PG et al²⁹ | Italy        | Multicenter, prospective cohort | 2,653         | 301 (12.7)                  | 1,325 (49.9) | NA                | NA           | NA    | Death    |
| Shi P et al³⁰  | China        | Multicenter, retrospective cohort | 134            | 5 (3.7)                     | 69 (51.5)  | 46                | NA           | 3 (2.2) | ICU       |
| Wan S et al³¹  | China        | Single-center cohort          | 135            | 4 (3.0)                     | 63 (46.7)  | 47                | 43 (31.9)    | 21 (15.6) | ICU       |
| Wang D et al³²  | China        | Single-center, retrospective cohort | 138           | 10 (7.2)                    | 63 (45.7)  | 56                | 64 (46.4)    | 27 (19.6) | ICU       |
| Wang L et al³³  | China        | Single-center, retrospective cohort | 339           | 15 (4.4)                    | 173 (51)   | 69                | NA           | 71 (21) | Death    |

(Continued on following page)
the search key phrase (“clinical characteristics” OR comorbidities OR cancer OR malignancy) AND (COVID-19 OR 2019-nCoV OR SARS-CoV-2) AND (mortality OR morbidity OR severity OR ICU OR outcomes). When searching CORD-19, we replaced Boolean operators “AND” and “OR” with the symbols “+” and “|”, respectively. When searching medRxiv, we used “COVID-19 cancer” as the main key phrase. Two authors (V.G.G. and E.P.) independently conducted the literature search and uploaded their findings in an online file storage service (Google Drive) to double-check them. They subsequently discussed the possibility of duplicate patient populations with the third author (I.I.S.).4

Data Extraction and Risk of Bias Assessment

Two authors (V.G.G. and E.P.) independently extracted data in a prespecified worksheet and cross-checked their findings. We collected data on type of publication, author, type of study, total patient population, outcomes of patients with versus without cancer, age, sex, and comorbidities. Authors of original contributions were contacted. Six authors provided us with additional information, which was incorporated in the findings of the meta-analysis. We assessed the methodological quality of the retrieved observational cohort studies with the Tool to Assess Risk of Bias in Cohort Studies, developed by the CLARITY Group at McMaster University.5 The tool uses 8 questions, with 4 possible answers in each. Clarifications on the risk-of-bias assessment are provided in the Data Supplement. Two authors (V.G.G. and E.P.) independently assessed the studies. The results were discussed with the third author (I.I.S.).

Outcomes of the Meta-Analysis

The primary outcomes of the meta-analysis were all-cause mortality and need for ICU admission. The latter outcome included either actual admission to the ICU or severe disease (such as application of invasive mechanical ventilation) that required admission to the ICU, even if the original study did not specify whether such patients were indeed admitted in the ICU (more details are provided in the Data Supplement). We did so because patients with severe disease might occasionally be unable to be admitted to the ICU because of unavailability of enough beds.

Statistical Analysis

We performed prespecified sensitivity analyses by calculating the pooled risk ratio (RR) of studies with low risk of bias and by excluding each study and recalculating the RR. We attempted prespecified subgroup analyses by age, type of cancer (solid tumor v hematologic malignancy), and country, but we were not able to perform the last 2 analyses because of unavailability of relevant data.

We conducted data synthesis using Review Manager 5.3 (RevMan 5.3) by the Cochrane Collaboration.6 We expressed pooled dichotomous effect measures as RR with 95% CI. We used a random-effects (DerSimonian and Laird) model. We measured the presence of statistical heterogeneity with $I^2$; interpreted according to the Cochrane Handbook recommendations; 0%-40%: might not be important; 30%-60%: may represent moderate heterogeneity; 50%-90%: substantial heterogeneity; 75%-100%: considerable heterogeneity.

### TABLE 1. Characteristics of Included Studies and Patient Population (Continued)

| Author          | Country | Type of Study                  | No. of Patients | No. of Patients With Cancer | Female Sex | Median Age (years) | Comorbidities | ARDS | Outcome |
|-----------------|---------|--------------------------------|-----------------|------------------------------|------------|--------------------|---------------|------|---------|
| Wang Z et al33  | China   | Single-center retrospective cohort | 69              | 4 (6)                        | 37 (54)    | 42                 | NA            | NA   | ICU     |
| Yan S et al34   | China   | Retrospective cohort            | 168             | 2 (1.2)                      | 87 (51.8)  | 51                 | NA            | 17   | (10.1)  |
| Yao Q et al35   | China   | Single-center, retrospective cohort | 108             | 2 (1.9)                      | 65 (60.2)  | 52                 | 25 (23.1)     | 45   | (41.7)  |
| Zhang G et al36 | China   | Single-center, retrospective cohort | 221             | 9 (4.1)                      | 113 (51.1) | 55                 | 78 (35.3)     | 48   | (21.7)  |
| Zhang J et al37 | China   | Single-center, retrospective cohort | 663             | 14 (2.1)                     | 342 (51.6) | 55.6               | 247 (37.3)    | NA   | Death, ICU |
| Zhang R et al38 | China   | Single-center, retrospective cohort | 120             | 7 (6)                        | 77 (64)    | NA                 | 32 (27)       | NA   | ICU     |
| Zhao W et al39  | China   | Single-center, retrospective cohort | 77              | 4 (5.2)                      | 43 (55.8)  | 56.5               | 24 (31.2)     | 3    | (3.9)   |
| Total/range     | —       | —                              | 46,499          | 1,776                        | 6,630      | 42-74              | 2,662         | 1,365 | —       |

NOTE. Data are expressed as No. (%) unless otherwise noted. ICU as outcome indicates patient was admitted to ICU or fulfilled criteria for admission in the ICU.

Abbreviations: ARDS, acute respiratory distress syndrome; ICU, intensive care unit; NA, not available.

*Goyal provided us with mortality data on communication.

*Rentsch provided us with updated mortality data as of April 23, on communication; the larger population is included in the mortality outcome.
### Table 2. Risk of Bias Assessment

| Study                | Q1 | Q2 | Q3 | Q4  | Q5  | Q6  | Q7  | Q8  | Low Risk |
|---------------------|----|----|----|-----|-----|-----|-----|-----|----------|
| Argenziano MG et al11 | Yes| Yes| Yes| No  | Yes | Yes | Yes | No  | Yes      |
| Benelli G et al12   | Yes| Yes| Yes| Yes | Yes | Yes | Yes | Yes | Yes      |
| Cai Q et al13       | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Cao M et al14       | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Chen T et al15      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Chen X et al16      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Chinese CDC17       | No | No | Yes| No  | Yes | No  | Yes | Yes | Yes      |
| Colaneri M et al18  | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Feng Y et al19      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Goyal P et al20     | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Guan W et al21      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Huang C et al22     | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Jiang X et al23     | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Joharzam-Hogan N et al24 | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Li X et al25        | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Miyashita H et al26 | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Myers L et al27     | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Nikpouraghdam M et al28 | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Petrelli CM et al29  | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Rentsch CT et al30  | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Rossi PG et al31    | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Shi P et al32       | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Wan S et al33       | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Wang D et al34      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Wang L et al35      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Wang Z et al36      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Yan S et al37       | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Yao Q et al38       | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Zhang G et al39     | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Zhang J et al40     | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Zhang R et al41     | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |
| Zhao W et al42      | Yes| Yes| Yes| No  | Yes | Yes | Yes | Yes | Yes      |

*Goyal and Rentsch provided us with mortality data on communication.
RESULTS

Figure 1 shows the flow diagram for study selection. Regarding mortality data from China, we excluded presumably duplicate publications with overlapping enrollment dates to include only 1 overarching report from the Chinese Center for Disease Control and Prevention (CDC). However, given that the latter report from the Chinese CDC did not provide specific data on old patients, we included these 2 studies in our subgroup analysis by age. A total of 32 studies (19 peer-reviewed, 13 preprints) involving 46,499 patients (1,776 patients with cancer) with COVID-19 from Asia, Europe, and the United States were included in our meta-analysis. Tables 1 and 2 list the summary characteristics and risk of bias assessment of the included studies, respectively.

All-Cause Mortality

Eight studies (37,807 total patients, 1,428 with cancer) provided data for all-cause mortality. No statistically significant heterogeneity was detected ($I^2 = 37\%$). All-cause mortality was higher in patients versus without cancer (2,034 deaths; RR, 1.66; 95% CI, 1.33 to 2.07; $P < .0001$; Fig 2).

Need for ICU Admission

Twenty-six studies (15,375 total patients, 801 with cancer) provided data for need for ICU admission. Moderate significant heterogeneity was detected ($I^2 = 53\%$). Patients with cancer were more likely to need ICU admission than patients without cancer (3,220 events; RR, 1.56; 95% CI, 1.31 to 1.87; $P < .0001$; Fig 3).

Sensitivity and Subgroup Analyses

In the sensitivity analysis of 4 studies with low risk of bias (8,804 total patients, 694 with cancer), all-cause mortality was higher in patients with versus without cancer (856 deaths; RR, 1.47; 95% CI, 1.04 to 2.09; $P = .03$).12,22,24,29 This was also the case for the sensitivity analyses by excluding each study and recalculating the RR.

In the prespecified subgroup analysis of 8 studies (5,438 patients, 505 with cancer), which provided data on mortality of patients > 65 years old, all-cause mortality was comparable between those with versus without cancer (915 deaths; RR, 1.06; 95% CI, 0.79 to 1.41; $P = .71$; Fig 4).

DISCUSSION

By performing the most comprehensive meta-analysis to date, which incorporated data from > 46,000 patients with COVID-19 across almost all continents, we quantified the effect of cancer on all-cause mortality (RR, 1.66; 95% CI, 1.33 to 2.07) and need for ICU admission (RR, 1.56; 95% CI, 1.31 to 1.87). Also, by performing a prespecified subgroup analysis, we revealed the interesting finding that among patients > 65 years of age, all-cause mortality was comparable between those with versus without cancer.

It is important to quantify the effect of cancer on outcomes of patients with COVID-19, as there are conflicting reports in the literature. Several studies indicated that patients with cancer are more likely to develop severe disease and are at increased risk for poor prognosis.10-42 They therefore encouraged clinicians to treat patients with cancer as an extremely vulnerable population. Those studies might also raise issues as to whether it is futile to admit patients with cancer and COVID-19 to the ICU.43 On the other hand, other studies suggested that there was no evidence of elevated mortality rates among infected patients with cancer.24,44 An interesting theory even suggested that immunocompromised patients, such as patients with cancer, may dampen the so-called "cytokine storm" because of downregulated immune response and thus have comparable or even better clinical outcomes.22,45 The results of our meta-analysis might help to reveal the true effect of cancer on mortality and need for ICU admission.

---

### Table 1: Risk Ratio for All-Cause Mortality and Need for ICU Admission

| Study or Subgroup | Cancer Events | Noncancer Events | Total Events | Total Weight (%) | Risk Ratio (95% CI) | Risk Ratio (95% CI) |
|-------------------|---------------|------------------|-------------|-----------------|-------------------|-------------------|
|                   | Cancer        | Noncancer        |             |                 | IV, Random        | IV, Random        |
| Benelli G et al   | 6             | 26               | 32          | 15.3            | 1.54 (0.90 to 2.98)| 1.54 (0.90 to 2.98) |
| Chinese CDC       | 6             | 26               | 32          | 15.3            | 2.07 (1.07 to 4.06)| 2.07 (1.07 to 4.06) |
| Goyal P et al     | 2             | 17               | 19          | 9.5             | 5.43 (1.91 to 14.48)| 5.43 (1.91 to 14.48) |
| Joharatnam-Hogan N et al | 6 | 26 | 32 | 15.3 | 1.99 (1.53 to 2.57) | 1.99 (1.53 to 2.57) |
| Miyashita H et al | 37            | 334              | 371         | 143             | 1.14 (0.46 to 3.01) | 1.14 (0.46 to 3.01) |
| Nikpouraghdam M et al | 1 | 17 | 18 | 9.0 | 0.73 (0.41 to 1.32) | 0.73 (0.41 to 1.32) |
| Rentsch CT et al  | 88            | 587              | 675         | 266             | 1.91 (1.53 to 2.37) | 1.91 (1.53 to 2.37) |
| Rossi PG et al    | 44            | 331              | 375         | 150             | 1.99 (1.46 to 2.71) | 1.99 (1.46 to 2.71) |
| **Total (95% CI)** | 1,428         | 36,379           | 37,807      | 100.0           | 1.66 (1.33 to 2.07)| 1.66 (1.33 to 2.07) |

Heterogeneity: $I^2 = 37\%$; Test for overall effect: $Z = 4.44 (P < .0001)$
An interesting finding of the meta-analysis was that, when data were collected from older patients, the increased mortality risk in the presence of cancer did not seem obvious. Regardless of cancer presence, increased age is considered a factor of worse prognosis. Furthermore, older individuals are characterized by an increased prevalence of comorbidities, which variably contribute to overall worse outcomes. On considering the

![Forest plot for need for intensive care unit admission. IV, inverse-variance.](image)

![Forest plot for age subgroup analysis. IV, inverse-variance.](image)
affirmed, the observed absence of increased mortality risk in older individuals does not conflict with the main findings of the study; it rather implies that the presence of cancer may not further affect the already burdened prognosis among individuals age > 65 years. Our meta-analysis has limitations. First, there are concerns for duplicate publications, which might skew the results of any meta-analysis. In an attempt to minimize this risk, we excluded studies on mortality conducted in the same region with overlapping enrollment dates and we included only the results of the largest cohort. Second, data were not available to perform meaningful subgroup analyses by type of cancer (including treatment and immunosuppressive status). However, through communications with authors of original studies, we were able to carry out an important subgroup analysis by age.

In conclusion, by accumulating data from 32 studies involving 46,499 patients (1,776 patients with cancer) with COVID-19 from Asia, Europe, and the United States, we quantified the effect of cancer on important clinical outcomes, such as mortality and need for ICU admission. We also found that elderly patients with cancer may not be at increased risk of death when infected with COVID-19. The findings of the meta-analysis are important to clinicians, because they can inform discussions with patients about prognosis. They may also guide health policies regarding protection of this vulnerable population.

**REFERENCES**

1. International Agency for Research on Cancer: Press Release N° 263. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. https://www.who.int/cancer/PRGlobocanFinal.pdf
2. Sawyer A, Straiton J: Are cancer patients more vulnerable to COVID-19? BioTechniques. https://www.biotechniques.com/coronavirus-news/news_are-cancer-patients-more-vulnerable-to-severe-outcomes-of-covid-19/
3. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700, 2009
4. Bauchner H, Golub RM, Zylke J: Editorial concern-possible reporting of the same patients with COVID-19 in different reports. JAMA 10.1001/jama.2020.3980 [pub ahead of print on March 16, 2020]
5. Tool to Assess Risk of Bias in Cohort Studies. Contributed by the CLARITY Group at McMaster University. https://www.evidencepartners.com/wp-content/uploads/2017/09/Tool-to-Assess-Risk-of-Bias-in-Cohort-Studies.pdf
6. Cochrane: Review Manager (RevMan), Version 5.3. Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration. 2014
7. Higgins JPT, Thomas J, Chandler J, et al (editors): Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. https://training.cochrane.org/handbook

**AFFILIATIONS**

1. First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York-Presbyterian Hospital–Weill Cornell Medical Center, Weill Cornell Medicine, New York, NY

**CORRESPONDING AUTHOR**

Ilias I. Siempos, MD, DSc, First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, National and Kapodistrian University of Athens Medical School, 45-47 Ipsiaplatou St, 10676 Athens, Greece; Twitter: @VIgiannakoulis; E-mail: isiempos@yahoo.com.

**EQUAL CONTRIBUTION**

V.G.G. and E.P. contributed equally to this work

**SUPPORT**

This study was supported by a grant from the Hellenic Thoracic Society (I.I.S.)

**AUTHOR CONTRIBUTIONS**

Conception and design: All authors
Collection and assembly of data: Vassilis G. Giannakoulis, Eleni Papoutsi
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc or ascopubs.org/go/site/misc/authors.html.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.

**ACKNOWLEDGMENT**

We thank Christopher T. Rentsch (VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven, CT), Parag Goyal (Weill Cornell Medicine, New York, NY), Khurum Khan (University College London, Hospital NHS Foundation Trust, UK), Francesco Ventura (Epidemiology Unit, Azienda Unità Sanitaria Locale–IRCCS di Reggio Emilia, Reggio Emilia, Italy), Giuseppe Lauria (Department of Clinical Neuroscience IRCCS Foundation “Carlo Besta” Neurologic Institute, Milan, Italy), and Mojtaba Sepandi (Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran) for showing praise-worthy academic attitude and generously providing us with additional data and clarifications regarding their studies.
8. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. http://weekly.chinacdc.cn/en/article/id/e53946e2-cbc4-41e9-9a9b-fea8b81a85f1

9. Chen T, Dai Z, Mo P, et al: Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): A single-centered, retrospective study. J Gerontol A Biol Sci Med Sci. 10.1093/gerona/gaa089 (epub ahead of print on April 11, 2020)

10. Wang L, He W, Yu X, et al: Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 80:639-645, 2020

11. Argenziano MG, Bruce SL, Slater CL, et al: Characterization and clinical course of 1000 patients with COVID-19 in New York: Retrospective case series. medRxiv 10.1101/2020.04.20.20072116

12. Benelli G, Buscanini E, Canetta C, et al: SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy. medRxiv 10.1101/2020.04.14.20053090

13. Cai Q, Huang D, Ou P, et al: COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy 10.1111/all.14309 (epub ahead of print on April 2, 2020)

14. Cao M, Zhang D, Wang Y, et al: Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. medRxiv 10.1101/2020.03.04.20030395

15. Chen X, Zheng F, Qing Y, et al: Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: A double-centered observational study. medRxiv 10.1101/2020.03.03.20030353

16. Colaneri M, Sacchi P, Zuccaro V, et al: Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill. 25:2000465, 2020

17. Feng Y, Ling Y, Bai T, et al: COVID-19 with different severity: A multi-center study of clinical features. Am J Respir Crit Care Med. 10.1164/rccm.202002-0445OC (epub ahead of print on April 10, 2020)

18. Goyal P, Choi JJ, Pinheiro LC, et al: Clinical characteristics of Covid-19 in New York City. N Engl J Med. 10.1056/NEJMc2010419 (epub ahead of print on April 17, 2020)

19. Guan WJ, Liang WH, Zhao Y, et al: Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J 55:2000547, 2020

20. Huang C, Wang Y, Li X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506, 2020

21. Jiang X, Tao J, Wu H, et al: Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China. medRxiv 10.1101/2020.04.10.20060335

22. Joharatnam-Hogan N, Hochhauser D, Shiu K-K, et al: Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer - a multi-centre North London experience. medRxiv 10.1101/2020.04.16.20061127

23. Li X, Xu S, Yu M, et al: Risk factors for severity and mortality in adult COVID-19 patients in Wuhan. J Allergy Clin Immunol. 10.1016/j.jaci.2020.04.006 (epub ahead of print on April 12, 2020)

24. Miyashita H, Mikami T, Chopra N, et al: Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 10.1016/j.annonc.2020.03.04.006 (epub ahead of print on April 21, 2020)

25. Myers LC, Parodi SM, Escobar GJ, et al: Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA. 10.1001/jama.2020.7202 (epub ahead of print on April 24, 2020)

26. Nikpourghadm M, Jalali Farahani A, Alishegi G, et al: Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: A single center study. J Clin Virol. 127:104378, 2020

27. Pettrill CM, Jones SA, Yang J, et al: Factors associated with hospitalization and critical illness among 4,100 patients with COVID-19 disease in New York City. medRxiv 10.1101/2020.04.08.20057794

28. Rentsch CT, Kidwai-Khan F, Tate JP, et al: Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States Veterans aged 54-75 years. medRxiv 10.1101/2020.04.16.20065964

29. Rossi PG, Marino M, Formisano D, et al: Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. medRxiv 10.1101/2020.04.13.20063545

30. Shi P, Ren G, Yang J, et al: Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study. medRxiv 10.1101/2020.04.20.20071472

31. Wann S, Xiang Y, Fang W, et al: Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 10.1002/jmv.25783 (epub ahead of print on March 21, 2020)

32. Wang D, Hu B, Hu C, et al: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Clin Virol. 32:1061-1069, 2020

33. Wang Z, Yang B, Li Q, et al: Clinical characteristics of 69 cases with coronavirus disease 2019 in Wuhan, China. J Infect. 80:639-645, 2020

34. Yan S, Song X, Lin F, et al: Clinical characteristics of coronavirus disease 2019 in Hainan, China. medRxiv 10.1101/2020.03.19.20038539

35. Yao Q, Wang P, Wang X, et al: Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients, Polish Arch Intern Med. 10.20452/pawm.15312 (epub ahead of print on April 24, 2020)

36. Zhang G, Hu C, Luo L, et al: Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China. medRxiv 10.1101/2020.03.02.20030452

37. Zhang J, Wang X, Jia X, et al: Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 10.1016/j.cmi.2020.04.012 (epub ahead of print April 15, 2020)

38. Zhang R, Ouyang H, Fu L, et al: CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol. 10.1007/s00330-020-06854-1 (epub ahead of print on April 11, 2020)

39. Zhao W, Yu S, Zha X, et al: Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: A retrospective cohort study. medRxiv 10.1101/2020.03.11.20035436

40. Zhang H-Y, Wang L-W, Chen Y-Y, et al: A multicentre study of 2019 novel coronavirus disease outcomes of cancer patients in Wuhan, China. medRxiv 10.1101/2020.03.21.20037127

41. Zhang L, Zhu F, Xie L, et al: Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 10.1016/j.annonc.2020.03.296 (epub ahead of print on March 26, 2020)

42. Ma J, Yin J, Qian Y, et al: Clinical characteristics and prognosis in cancer patients with COVID-19: A single center’s retrospective study. J Infect. 10.1016/j.jinf.2020.04.006 (epub ahead of print on April 14, 2020)

43. Koutsoukou A: Admission of critically ill patients with cancer to the ICU: Many uncertainties remain. ESMO Open 2:e000105, 2017
44. Narozniak R: Clinical factors predict deterioration among patients with cancer, COVID-19. https://www.onclive.com/conference-coverage/aacr-2020/aacr-2020-clinical-factors-predict-deterioration-among-patients-with-cancer-covid19?p=2
45. Spezzani V, Piunno A, Iselin HU: Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple. Swiss Med Wkly 150:w20246, 2020
46. Bialek S, Boundy E, Bowen V, et al: Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 69:343-346, 2020
47. Zhou F, Yu T, Du R, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395:1054-1062, 2020
48. Wolff JL, Starfield B, Anderson G: Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 162:2269-2276, 2002